The TRUCKEE study found improvements in visual acuity and reductions in central subfield thickness (CST) for patients treated with faricimab for neovascular age-related macular degeneration (nAMD), according to an analysis published in Eye. The real-world research also shows that faricimab is well-tolerated with a low rate of treatable intraocular inflammation.
Researchers conducted a multicenter, retrospective chart review of 376 eyes from 335 patients (average age, 79.8 years; age range, 44–100 years; 185 women, 150 men) with nAMD who were treated with faricimab between February 2022 and September 2022. The TRUCKEE study investigators collected data including demographics, treatment history, best-corrected visual acuity (BCVA), anatomic changes, and adverse events. The primary outcome measures were changes in BCVA, changes in CST and adverse events.
Following 1 injection of faricimab, all eyes (n=376), previously-treated eyes (n=337) and treatment-naïve eyes (n=39) had a + 1.1 letter (P =.035), a + 0.7 letter (P =.196) and a + 4.9 letter (P =.076) improvement in BCVA, respectively, and a − 31.3 μM (P <.001), a − 25.3 μM (P <.001) and a − 84.5 μM (P <.001) decrease in CST, respectively.
Following 3 injections of faricimab, all eyes (n=94), previously-treated (n=81) and treatment-naïve (n=13) eyes had a + 3.4 letter (P =.03), a + 2.7 letter (P =.045) and a + 8.1 letter (P =.437) improvement in BCVA, and a − 43.4 µm (P <.001), a − 38.1 µm (P <.001) and a − 80.1 µm (P <.204) decrease in CST, respectively.
The TRUCKEE study did demonstrate 1 case of intraocular inflammation after 4 injections of faricimab which resolved with topical steroids. There was also 1 case of infectious endophthalmitis which resolved with intravitreal antibiotics.
“Faricimab is the first bispecific antibody approved to treat nAMD and is the newest treatment option for the treatment of nAMD,” according to the researchers. “The six months results from the TRUCKEE study with efficacy and safety data of one and three injections of faricimab highlight the benefit of faricimab in treatment naïve as well as previously-treated patients with nAMD.”
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. Published online May 12, 2023. doi:10.1038/s41433-023-02553-5